These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1136 related articles for article (PubMed ID: 21486284)

  • 1. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
    Duty S; Jenner P
    Br J Pharmacol; 2011 Oct; 164(4):1357-91. PubMed ID: 21486284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease.
    Thiele SL; Warre R; Nash JE
    J Vis Exp; 2012 Feb; (60):. PubMed ID: 22370630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
    Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.
    Jenner P
    Ann Neurol; 2008 Dec; 64 Suppl 2():S16-29. PubMed ID: 19127585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of L-DOPA-induced dyskinesia: an update on the current options.
    Iderberg H; Francardo V; Pioli EY
    Neuroscience; 2012 Jun; 211():13-27. PubMed ID: 22465440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.
    Jenner P
    Parkinsonism Relat Disord; 2003 Jan; 9(3):131-7. PubMed ID: 12573867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
    Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
    Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
    Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
    Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
    Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
    Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling dyskinesia in animal models of Parkinson disease.
    Morin N; Jourdain VA; Di Paolo T
    Exp Neurol; 2014 Jun; 256():105-16. PubMed ID: 23360802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.